Headline: Administering Radium-223 along with metastasis directed therapy for oligometastatic prostate cancer does not further delay disease progression.
The Study: Metastasis directed therapy alone delays progression in patients with oligometastatic prostate cancer. In the RAVENS trial, 64 men with oligometastatic prostate cancer received MTD +/- 6 cycles of Radium-223. Median PFS was 10.4 months with MDT+Radium and 10.2 months without.
TBL: In this randomized trial of patients receiving MDT alone for oligometastatic prostate cancer, the addition of radium-223 did not delay progression. | Tran, ASTRO 2024
The Study: Metastasis directed therapy alone delays progression in patients with oligometastatic prostate cancer. In the RAVENS trial, 64 men with oligometastatic prostate cancer received MTD +/- 6 cycles of Radium-223. Median PFS was 10.4 months with MDT+Radium and 10.2 months without.
TBL: In this randomized trial of patients receiving MDT alone for oligometastatic prostate cancer, the addition of radium-223 did not delay progression. | Tran, ASTRO 2024